Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients - PubMed
4 hours ago
- #olezarsen
- #monocyte activation
- #hypertriglyceridemia
- Olezarsen is a drug that lowers fasting and postprandial triglycerides.
- In a trial with hypertriglyceridemic patients, olezarsen reduced postprandial triglyceride area under the curve by 55%.
- Olezarsen decreased intracellular lipid droplets in monocytes by 25.0% after a fat load.
- It reduced activation markers CD11c, CD11b, and CD16 in peripheral blood mononuclear cells.
- Postprandial interleukin-1beta gene expression in monocytes was lowered with olezarsen.
- Monocyte adhesion decreased by 14.4% in an ex vivo migration assay after treatment.
- Olezarsen attenuates pro-inflammatory changes by reducing lipid-driven immune-cell activation.